Ildong Pharmaceutical Co., Ltd. Statistics
Want to see KR:249420 full AI Analyst Report?
Ildong Pharmaceutical Co., Ltd. (249420) Stock Statistics & Valuation Metrics
Total Valuation
Ildong Pharmaceutical Co., Ltd. has a market cap or net worth of KRW 388.61B. The enterprise value is KRW 499.19B.
- Market Cap
- KRW 388.61B
- Enterprise Value
- KRW 499.19B
Share Statistics
Ildong Pharmaceutical Co., Ltd. has 31,638,252 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 31,638,252
- Owned by Insiders
- ―
- Owned by Institutions
- 4.54%
Financial Efficiency
Ildong Pharmaceutical Co., Ltd.’s return on equity (ROE) is 0.11 and return on invested capital (ROIC) is 2.79%.
- Return on Equity (ROE)
- 0.11
- Return on Assets (ROA)
- 0.05
- Return on Invested Capital (ROIC)
- 2.79%
- Return on Capital Employed (ROCE)
- 0.05
- Revenue Per Employee
- 513.53M
- Profits Per Employee
- 25.06M
- Employee Count
- 1,104
- Asset Turnover
- 0.99
- Inventory Turnover
- 3.50
Valuation Ratios
The current PE Ratio of Ildong Pharmaceutical Co., Ltd. is 21.92. Ildong Pharmaceutical Co., Ltd.’s PEG ratio is -0.52.
- PE Ratio
- 21.92
- PS Ratio
- 0.64
- PB Ratio
- 1.48
- Price to FCF
- 15.97
- Price to Operating Cash Flow
- 10.74
- PEG Ratio
- -0.52
Income Statement
In the last 12 months, Ildong Pharmaceutical Co., Ltd. had revenue of 566.93B and earned 27.66B in profits. Earnings per share was 942.08.
- Revenue
- 566.93B
- Gross Profit
- 214.76B
- Operating Income
- 17.32B
- Pretax Income
- 31.80B
- Net Income
- 27.66B
- EBITDA
- 39.90B
- Earnings Per Share (EPS)
- 942.08
Cash Flow
In the last 12 months, operating cash flow was 39.15B and capital expenditures -8.24B, giving a free cash flow of 30.91B billion.
- Operating Cash Flow
- 39.15B
- Free Cash Flow
- 30.91B
- Free Cash Flow per Share
- 750.09
Dividends & Yields
Ildong Pharmaceutical Co., Ltd. pays an annual dividend of ―, resulting in a dividend yield of 1.63%
- Dividend Per Share
- ―
- Dividend Yield
- 1.63%
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 6.13%
- Earnings Yield
- 4.33%
Stock Price Statistics
- Beta
- 0.27
- 52-Week Price Change
- -56.88%
- 50-Day Moving Average
- 13561.00
- 200-Day Moving Average
- 20439.14
- Relative Strength Index (RSI)
- 42.58
- Average Volume (3m)
- 296.27K
Important Dates
Ildong Pharmaceutical Co., Ltd. upcoming earnings date is Mar 18, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 16, 2026
- Next Earnings Date
- Mar 18, 2027
- Ex-Dividend Date
- ―
Financial Position
Ildong Pharmaceutical Co., Ltd. as a current ratio of 0.96, with Debt / Equity ratio of 61.00%
- Current Ratio
- 0.96
- Quick Ratio
- 0.53
- Debt to Market Cap
- 0.10
- Net Debt to EBITDA
- 2.14
- Interest Coverage Ratio
- 1.42
Taxes
In the past 12 months, Ildong Pharmaceutical Co., Ltd. has paid 8.08B in taxes.
- Income Tax
- 8.08B
- Effective Tax Rate
- 0.25
Enterprise Valuation
Ildong Pharmaceutical Co., Ltd. EV to EBITDA ratio is -13.54, with an EV/FCF ratio of 20.05.
- EV to Sales
- 0.81
- EV to EBITDA
- -13.54
- EV to Free Cash Flow
- 20.05
- EV to Operating Cash Flow
- 13.43
Balance Sheet
Ildong Pharmaceutical Co., Ltd. has KRW 70.38B in cash and marketable securities with KRW 134.36B in debt, giving a net cash position of -KRW 63.98B billion.
- Cash & Marketable Securities
- KRW 70.38B
- Total Debt
- KRW 134.36B
- Net Cash
- -KRW 63.98B
- Net Cash Per Share
- -KRW 2,022.22
- Tangible Book Value Per Share
- KRW 0.00
Margins
Gross margin is 28.08%, with operating margin of 4.41%, and net profit margin of 2.86%.
- Gross Margin
- 28.08%
- Operating Margin
- 4.41%
- Pretax Margin
- 2.75%
- Net Profit Margin
- 2.86%
- EBITDA Margin
- -5.98%
- EBIT Margin
- -8.76%
Analyst Forecast
The average price target for Ildong Pharmaceutical Co., Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 2.12%
- EPS Growth Forecast
- -44.69%
Scores
- Smart Score
- ―
- AI Score
- 57

